Trials / Recruiting
RecruitingNCT07019220
Chemoablation for Low-Grade Bladder Cancer
COBRA - Chemoablation for Low Grade Bladder Cancer: A Single Arm, Prospective, Open-label, Investigator-initiated Phase 2 Study
- Status
- Recruiting
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 47 (estimated)
- Sponsor
- Ekaterina Laukhtina · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The goal of this single arm, prospective, open-label, investigator-initiated Phase 2 clinical trial is to evaluate the efficacy of intravesical chemoablation in patients with low grade bladder cancer.
Detailed description
In this study, patients with histologically confirmed Ta low-grade bladder cancer will undergo chemoablation with gemcitabine (six weekly instillations). The study aims to evaluate the efficacy, safety, and tolerability of chemoablation.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Gemcitabine | Intravesical installation |
Timeline
- Start date
- 2023-12-27
- Primary completion
- 2027-11-01
- Completion
- 2027-11-01
- First posted
- 2025-06-13
- Last updated
- 2025-06-13
Locations
1 site across 1 country: Austria
Source: ClinicalTrials.gov record NCT07019220. Inclusion in this directory is not an endorsement.